Clinical value of interleukin - 6 as a potential biomarker for bronchogenic carcinoma: A clinical study.

Background: Bronchogenic carcinoma, a predominant form of lung cancer, continues to challenge diagnostic modalities with its late detection and poor prognosis. Interleukin-6 (IL-6), a cytokine involved in inflammatory and immune responses, has recently been scrutinized for its potential role as a biomarker in various cancers. This clinical study evaluates the clinical value of IL-6 levels in patients with bronchogenic carcinoma, aiming to establish its utility in early diagnosis and prognosis estimation. Materials and Methods: A total of 200 participants were enrolled in this study, divided evenly into two groups: patients diagnosed with bronchogenic carcinoma and a control group of healthy individuals. Serum IL-6 levels were measured using enzyme-linked immunosorbent assay (ELISA). The study also assessed the correlation of IL-6 levels with disease stage, tumor size, and patient survival rates. Statistical analysis was performed using SPSS software, employing t-tests and chi-square tests where applicable. Results: The study found significantly higher levels of IL-6 in patients with bronchogenic carcinoma compared to the control group (mean IL-6 levels of 45 pg/mL vs. 12 pg/mL, respectively; p<0.001). Further, IL-6 levels correlated positively with advanced disease stage and larger tumor size. Patients with IL-6 levels above 60 pg/mL had a significantly lower 5-year survival rate (30%) compared to those with levels below 60 pg/mL (65%). Conclusion: Elevated IL-6 levels are associated with bronchogenic carcinoma and correlate with disease severity and lower survival rates. These findings suggest that IL-6 can serve as a valuable biomarker for the early detection and prognosis of bronchogenic carcinoma. Further studies are recommended to validate these findings and explore the therapeutic potential of targeting IL-6 in lung cancer treatment. [ABSTRACT FROM AUTHOR]